Polymorphism of the complement 5 gene and cardiovascular outcome in patients with atherosclerosis

European Journal of Clinical Investigation

Volumn 42, Issue 9, 2012, Pages 921-926

  Hoke, Matthias ^a   Speidl, Walter ^a   Schillinger, Martin ^a   Minar, Erich ^a   Zehetmayer, Sonja ^a   Schönherr, Michael ^a   Wagner, Oswald ^a   Mannhalter, Christine ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cardiovascular outcome; Carotid atherosclerosis; Complement system; Single nucleotide polymorphism

Indexed keywords

COMPLEMENT COMPONENT C5A;

ADULT; AGED; ARTICLE; CAROTID ATHEROSCLEROSIS; COMPLEMENT 5 GENE; COMPLEMENT SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; GENE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE;

AGED; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMPLEMENT C5; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 84865186771     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02669.x     Document Type: Article

References (22)

1. Libby P, Ridker P, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.
2. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 2001;104:503-16.
3. Niculescu F, Rus H. The role of complement activation in atherosclerosis. Immunol Res 2004;30:73-80.
4. Pesarini G, Amoruso A, Ferrero V, Bardelli C, Fresu LG, Perobelli L et al. Cytokines release inhibition from activated monocytes, and reduction of in-stent neointimal growth in humans. Atherosclerosis 2010;211:242-8.
5. Granger CB, Mahaffey KW, Weaver WD, Theroux P, Hochman JS, Filloon TG et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003;108:1184-90.
6. Casas JP, Hingorani AD, Bautista LE, Sharma P. Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18, 000 cases and 58, 000 controls. Arch Neurol 2004;61:1652-61.
7. Bare LA, Morrison AC, Rowland CM, Shiffman D, Luke MM, Iakoubova OA et al. Five common gene variants identify elevated genetic risk for coronary heart disease. Genet Med 2007;9:682-9.
8. Greisenegger S, Zehetmayer S, Bauer P, Endler G, Ferrari J, Lang W et al. Polymorphisms in inflammatory genes and the risk of ischemic stroke and transient ischemic attack: results of a multilocus genotyping assay. Clin Chem 2009;55:134-8.
9. Schillinger M, Exner M, Mlekusch W, Sabeti S, Amighi J, Nikowitsch R et al. Inflammation and Carotid Artery - Risk for Atherosclerosis Study (ICARAS). Circulation 2005;111:2203-9.
10. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
11. Simera I, Altman DG, Moher D, Schulz KF, Hoey J. Guidelines for reporting health research: the EQUATOR network's survey of guideline authors. PLoS Med 2008;5:e139.
12. Saiki RK, Walsh PS, Levenson CH, Erlich HA. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc Natl Acad Sci U S A 1989;86:6230-4.
13. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000;36:959-69.
14. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989;20:864-70.
15. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132-40.
16. Pucci A, Brscic E, Tessitore E, Celeste A, Crudelini M, De Bernardi A et al. C-reactive protein and coronary composition in patients with percutaneous revascularization. Eur J Clin Invest 2008;38:281-9.
17. Czermak BJ, Sarma V, Bless NM, Schmal H, Friedl HP, Ward PA. In vitro and in vivo dependency of chemokine generation on C5a and TNF- alpha. J Immunol 1999;162:2321-5.
18. Helske S, Oksjoki R, Lindstedt KA, Lommi J, Turto H, Werkkala K et al. Complement system is activated in stenotic aortic valves. Atherosclerosis 2008;196:190-200.
19. Speidl WS, Exner M, Amighi J, Mlekusch W, Sabeti S, Kastl SP et al. Complement component C5a predicts restenosis after superficial femoral artery balloon angioplasty. J Endovasc Ther 2007;14:62-9.
20. Appelboom G, Piazza M, Hwang BY, Bruce S, Smith S, Bratt A et al. Complement Factor H Y402H polymorphism is associated with an increased risk of mortality after intracerebral hemorrhage. J Clin Neurosci 2011;18:1439-43.
21. Jeong JC, Hwang YH, Kim H, Ro H, Park HC, Kim YJ et al. Association of complement 5 genetic polymorphism with renal allograft outcomes in Korea. Nephrol Dial Transplant 2011;26:3378-85.
22. Goulart AC, Rexrode KM, Cheng S, Rose L, Buring JE, Ridker PM et al. Association of genetic variants with the metabolic syndrome in 20, 806 white women: the Women's Health Genome Study. Am Heart J 2009;158:257-62.e1.